Successful Treatment with Topical Diphenylcyclopropenone for Three Cases of Anogenital Warts in Children

Go, Usho; Fujita, Masatoshi; Mitsuishi, Tsuyoshi

doi:10.1159/000500295

Cited by 7 publications

(5 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…All lesions were fully regressed after 6 months. 12 Also, Yen and his coworkers applied topical 0.1% DPCP solution once every 2 weeks for 2 months to a large condyloma acuminatum of Buschke and Löwenstein; the authors concluded that the treatment was well tolerated, and the lesion disappeared completely after 6 months. 8 On the other hand, Suh and his colleagues reported that the complete clearance of viral warts located on the hands, feet, and other sites was achieved in 82.9% of patients.…”

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

“…11 Only a few case reports have shown that DPCP can successfully cure AGWs. 8,12 Nonetheless, there are no randomized clinical trials on its use in AGWs.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Effectiveness and safety of topical application of diphenylcyclopropenone versus podophyllin in treatment of genital warts

Halim

Ahmed²,

Eyada

2023

Int J STD AIDS

View full text Add to dashboard Cite

Background Many therapeutic modalities are available for treating genital warts; however, the effectiveness of both diphenylcyclopropenone and podophyllin is still controversial. Aim To evaluate the effectiveness and safety of diphenylcyclopropenone and podophyllin in treating genital warts. Methods This study included 57 patients, divided randomly into two groups. Group (A): diphenylcyclopropenone ( n = 29). Group (B): podophyllin 25% ( n = 28). In group (A), sensitization was done with 2% diphenylcyclopropenone. Then, after 1 or 2 weeks, treatment started with a weekly application of diphenylcyclopropenone solutions ranging between 0.001 and 1% until clearance, or for a maximum of 10 sessions. In group (B), podophyllin 25% was applied weekly until clearance or for a maximum of 6 weeks. Results Higher clearance was achieved in group A, with 19 of 29 (65.5%) patients, than in group B, with 9 of 28 (32.1%) ( p-value = 0.004). Also, effectiveness increases with young age in group A. Shorter wart duration was associated with better response in both groups ( p-value = 0.005). No serious adverse effects occurred in either group. No recurrence was detected in group A, while seven patients (77.8%) had recurrence in group B after 1 year of follow up. Conclusion Diphenylcyclopropenone shows a higher success rate than podophyllin in treating genital warts and a lower recurrence rate.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Effectiveness and safety of topical application of diphenylcyclopropenone versus podophyllin in treatment of genital warts

Halim

Ahmed²,

Eyada

2023

Int J STD AIDS

View full text Add to dashboard Cite

show abstract

“…Except for cutaneous warts, anogenital warts (condyloma acuminatum) can also be treated by DNCB [ 78 , 79 ], SADBE [ 45 ], and DPCP [ 29 , 80 ], offering an alternative treatment option besides local application of podophyllum resin and 5-fluorouracil (5-FU), electrodessication, cryotherapy, and laser therapy [ 78 ]. However, clinical trials on a larger scale are needed to prove the efficacy.…”

Section: Topical Immunotherapy In the Treatment Of Skin Diseasesmentioning

confidence: 99%

Use of Contact Immunotherapy in the Treatment of Skin Diseases Other than Alopecia Areata

Lai

Tsai

2022

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

For decades, contact immunotherapy with dinitrochlorobenzene, diphencyprone, and squaric acid dibutylester has played an important role in both clinical practice and scientific research. It is listed as the first-line treatment for extensive alopecia areata and was more recently approved for melanoma treatment as an orphan drug in the USA. Moreover, owing to the relative low cost and safety, topical immunotherapy has also been used in many infectious, neoplastic, and inflammatory dermatological diseases. It is especially valuable in vulnerable groups, for cosmetic/pain sensitive areas, or for multiple lesions. In this review, we summarize the current evidence supporting the use of contact immunotherapy for treatment of skin diseases, from articles collected from PubMed database. Owing to space limitation and already numerous studies focusing on alopecia areata, we include only skin diseases other than alopecia areata. In addition to diseases that have been reported to be treated by contact immunotherapy, the hypothesized mechanism, prognosis prediction, efficacy, and safety of these topical agents are discussed.

show abstract

“…Topical medications such as imiquimod 5%, podofilox 0.5%, sinecatechins ointment 15% and diphenylcyclopropenone have been used in children with encouraging results. 1,4,5 Imiquimod is an immune stimulator that acts on the Toll-like receptors (TLRs)-7 and 8 and enhances production of interferons, tumor necrosis factor-α and interleukins-1, 6 and 8.…”

mentioning

confidence: 99%

Florid anogenital warts in a 7‐month‐old boy with rapid response to imiquimod

Bhandari

Khunger

Khullar

et al. 2022

Dermatologic Therapy

View full text Add to dashboard Cite

Successful Treatment with Topical Diphenylcyclopropenone for Three Cases of Anogenital Warts in Children

Cited by 7 publications

References 12 publications

Effectiveness and safety of topical application of diphenylcyclopropenone versus podophyllin in treatment of genital warts

Effectiveness and safety of topical application of diphenylcyclopropenone versus podophyllin in treatment of genital warts

Use of Contact Immunotherapy in the Treatment of Skin Diseases Other than Alopecia Areata

Florid anogenital warts in a 7‐month‐old boy with rapid response to imiquimod

Contact Info

Product

Resources

About